Marilyn Carlson - Evoke Pharma Chief Medical Officer
| EVOK Stock | USD 4.35 0.02 0.46% |
Executive
Dr. Marilyn R. Carlson D.M.D., M.D., RAC., is Chief Medical Officer since December 2013. Dr. Carlson has worked closely with Evoke since the company was founded in 2007 and her appointment is a significant step for the company as we gear up to begin our Phase 3 clinical trial. Dr. Carlson was the key clinical and regulatory expert for Evoke through the entire development of EVK001, including the most recent successful Phase 2b trial in gastroparesis. She has also participated in all of Evoke meetings with the U.S. Food Drug Administration . Dr. Carlson brings an enormous amount of talent and knowledge to Evoke and will be instrumental in the process we have ahead of us to reach FDA approval for EVK001. Her track record in development of regulatory strategies and submissions and proven ability to drive clinical development will be invaluable to our efforts. Dr. Carlson has more than 22 years of experience in the development and postmarketing support of drugs, biologics, devices and diagnostics. She is one of the founders of Agility Clinical, Inc., a contract research organization dedicated to working with biotechnology companies and companies focused on orphan drug development, and is the founder of entreMeDica, a consulting company that provides chief medical officer services to biotechnology and life sciences companies since 2013.
| Age | 76 |
| Tenure | 11 years |
| Address | 420 Stevens Avenue, Solana Beach, CA, United States, 92075 |
| Phone | 858 345 1494 |
| Web | https://www.evokepharma.com |
Marilyn Carlson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Marilyn Carlson against Evoke Pharma stock is an integral part of due diligence when investing in Evoke Pharma. Marilyn Carlson insider activity provides valuable insight into whether Evoke Pharma is net buyers or sellers over its current business cycle. Note, Evoke Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Evoke Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Marilyn Carlson over two months ago Acquisition by Marilyn Carlson of 75000 shares of Evoke Pharma at 0.62 subject to Rule 16b-3 |
Evoke Pharma Management Efficiency
The company has return on total asset (ROA) of (0.335) % which means that it has lost $0.335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4991) %, meaning that it created substantial loss on money invested by shareholders. Evoke Pharma's management efficiency ratios could be used to measure how well Evoke Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 3.17 this year, although the value of Return On Tangible Assets will most likely fall to (1.16). At this time, Evoke Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to about 101.4 K this year, although the value of Total Current Liabilities will most likely fall to about 2.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alycia Torres | Biofrontera | N/A | |
| Stephen Wargacki | Aquestive Therapeutics | 46 | |
| Timothy CPA | Shuttle Pharmaceuticals | 66 | |
| Carlos Russo | Procaps Group SA | 39 | |
| Sherry Korczynski | Aquestive Therapeutics | N/A | |
| Erin Gull | Cumberland Pharmaceuticals | N/A | |
| Carl MD | Aquestive Therapeutics | 54 | |
| Natalie May | Incannex Healthcare Ltd | N/A | |
| Jaclyn Jaffe | Journey Medical Corp | N/A | |
| Ramsey Alloush | Journey Medical Corp | 38 | |
| Jason Vaughn | Avadel Pharmaceuticals PLC | N/A | |
| MBA MD | Aquestive Therapeutics | 66 | |
| Gene Esq | Shuttle Pharmaceuticals | N/A | |
| Samantha Widdicombe | Biofrontera | N/A | |
| Mark Elrod | Avadel Pharmaceuticals PLC | N/A | |
| Chris Bitterman | Cumberland Pharmaceuticals | 59 | |
| Todd Anthony | Cumberland Pharmaceuticals | 63 | |
| Joseph Benesch | Journey Medical Corp | 57 | |
| Ernest Toth | Aquestive Therapeutics | 65 | |
| Jon MBA | Biofrontera | N/A | |
| Huang CFA | China Pharma Holdings | N/A | |
Management Performance
| Return On Equity | -3.5 | ||||
| Return On Asset | -0.33 |
Evoke Pharma Leadership Team
Elected by the shareholders, the Evoke Pharma's board of directors comprises two types of representatives: Evoke Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evoke. The board's role is to monitor Evoke Pharma's management team and ensure that shareholders' interests are well served. Evoke Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evoke Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David RPh, CEO CoFounder | ||
| Mark CPA, Chief Officer | ||
| David Gonyer, CEO, Founder, Director | ||
| Matthew MBA, President CoFounder | ||
| DMD MD, Chief Officer | ||
| Christopher Quesenberry, Chief Gimoti | ||
| Marilyn Carlson, Chief Medical Officer | ||
| Matthew DOnofrio, Executive Vice President Chief Business Officer Treasurer, Secretary , |
Evoke Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evoke Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.5 | ||||
| Return On Asset | -0.33 | ||||
| Profit Margin | (0.71) % | ||||
| Operating Margin | (0.48) % | ||||
| Current Valuation | 95.39 K | ||||
| Shares Outstanding | 1.49 M | ||||
| Shares Owned By Insiders | 4.59 % | ||||
| Shares Owned By Institutions | 17.12 % | ||||
| Number Of Shares Shorted | 101.01 K | ||||
| Price To Earning | (3.21) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share 7.792 | Quarterly Revenue Growth 0.698 | Return On Assets (0.34) | Return On Equity (3.50) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.